Skip to main content

Table 1 Characteristics of patients (N = 225) and overall survival (OS)

From: TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy

Variables Patients No. (%) Deaths No. (%) MST (Months) Log-rank P a
Age     
   ≤62 years 111 (49.3) 72 (46.5) 25.6 0.117
   >62 years 114 (50.7) 83 (53.5) 21.1  
Gender     
   Female 102 (45.3) 65 (41.9) 26.7 0.036
   Male 123 (54.5) 90 (58.1) 22.3  
Ethnicity     
   White 162 (72.0) 117 (75.5) 23.5 0.827
   Non-White 63 (28.0) 38 (24.5) 22.3  
Smokeb     
   Ever 205 (91.5) 143 (92.9) 23.4 0.457
   Never 19 (8.5) 11 (7.1) 21.1  
Histology     
   Adenocarcinoma 79 (35.1) 48 (31.0) 27.3 0.092
   Squamous cell 71 (31.6) 51 (32.9) 23.2  
   Others b 75 (33.3) 56 (36.1) 19.0  
KPSc     
   90-100 51 (25.4) 34 (22.7) 25.1 0.405
   80 118 (58.7) 90 (60.0) 22.1  
   <80 32 (15.9) 26 (17.3) 21.1  
Tumor stage c     
   T0-2 127 (57.2) 81 (52.3) 26.9 0.010
   T3-4 95 (42.8) 74 (47.7) 19.2  
Node status c     
   N0-1 59 (26.7) 35 (22.6) 29.0 0.023
   N2-3 162 (73.3) 120 (77.4) 20.7  
Chemotherapy     
   Yes 163 (72.4) 113 (72.9) 26.9 0.407
   No 62 (27.6) 42 (27.1) 22.1  
Radiotherapy dosed     
   ≤63.0 Gy 115 (51.1) 77 (49.7) 22.7 0.706
   >63.0 Gy 110 (48.9) 78 (50.3) 25.1  
  1. MST: median survival time; KPS: Karnofsky's performance scores
  2. a Log-rank test.
  3. b Others include large cell, undifferentiated and mixed-cell carcinomas.
  4. c Some missing data.
  5. dThe median radiotherapy dose is 63 Gy.